e-learning
resources
Milan 2017
Wednesday, 13.09.2017
New perspectives from experimental models of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor
K. Wilson (GLASGOW, United Kingdom)
Source:
International Congress 2017 – New perspectives from experimental models of pulmonary hypertension
Session:
New perspectives from experimental models of pulmonary hypertension
Session type:
Oral Presentation
Number:
4663
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Wilson (GLASGOW, United Kingdom). Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor. 4663
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Two rat models of hemolysis-induced pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Reversibility of the monocrotaline pulmonary hypertension rat model
Source: Eur Respir J 2013; 42: 553-556
Year: 2013
Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model
Source: International Congress 2017 – Experimental PH
Year: 2017
Effects of HIV protease inhibitors on monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Treatment effects of Rho-kinase (Rock) inhibition
vs.
phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 547s
Year: 2006
Hypoxia-induced pulmonary artery fibroblast proliferation and migration is prevented by ASK1 inhibition in an in vitro cellular model of pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Activation of AMPK inhibits pulmonary arterial remodeling
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept